icaria-MM: sarclisa + POMALIDOMIDE AND DEXAMETHASONE (Pd)

icaria-MM Patient
Profiles

Treating with sarclisa + Pd as early as
first relapse1

Current patient information

68 years of age

Cytogenetic risk
High: t(4;14)
ECOG PS 0
Cardiovascular comorbidities
ECG shows EF 45%,
uncontrolled hypertension
Older age

Diagnosis

Diagnosed 3 years ago after work-up for fatigue revealed anemia

1st line

VRd induction → ASCT → bortezomib and lenalidomide maintenance (CR for 30 months posttransplant)

1st relapse

Peripheral neuropathy; relapsed with new lesion in humerus found on MRI

2nd-line treatment considerations for Laura

  • High cytogenetic risk
  • Cardiovascular comorbidities
  • Double refractory to lenalidomide and bortezomib
  • Candidate for a triplet combination that includes a multimodal anti-CD38 mAb and a third-generation IMiD®

consider sarclisa + Pd as early as first relapsefor patients with high cytogenetic risk and patients with cardiovascular
comorbidities1

PFS in the intent-to-treat population1

  • mPFS: 11.53 months with SARCLISA + Pd (n=154) vs 6.47 months with Pd alone (n=153), HR=0.596 (95% CI: 0.44, 0.81; P=0.0010)

This is a hypothetical case study portrayed by an actor and should not substitute a healthcare provider's decision.

ASCT=autologous stem cell transplant; CR=complete response; ECG=electrocardiogram; ECOG PS=Eastern Cooperative Oncology Group performance status; EF=ejection fraction; IMiD=immunomodulatory drug; mAb=monoclonal antibody; mPFS=median progression-free survival; MRI=magnetic resonance imaging; PFS=progression-free survival; RRMM=relapsed or refractory multiple myeloma; VRd=bortezomib, lenalidomide, dexamethasone.

PFS results in patients with high cytogenetic risk
and patients refractory to lenalidomide

In icaria-MM, 20% of patients had high cytogenetic risk* and 93%
were refractory to lenalidomide1

PFS in patients with high cytogenetic risk2,3

34%
Reduction in the risk of
disease progression
HR=0.66 (95% CI: 0.33, 1.28)

PFS in patients refractory to lenalidomide4

41%
Reduction in the risk of
disease progression
HR=0.59 (95% CI: 0.43, 0.82)

See the full icaria-mm patient subgroup data

Study limitations

Prespecified subgroup analysis; subgroups were not powered to show differences between treatment arms.

*Cytogenetics by central lab; cutoff 50% for del(17p), 30% for t(4;14) and t(14;16).3

Review the broad and diverse patient population studied in the phase 3 ICARIA-MM trial1

See ICARIA-MM Trial Design

Get in touch with your local SARCLISA representative

Contact a Rep
View Ben's Profile

Current patient information

78 years of age

Cytogenetic risk
Standard
ECOG PS 1
Elderly
Renal function
(eGFR)
48 mL/min/1.73 m2

Diagnosis

Diagnosed ~3.5 years ago after presenting with anemia, moderate renal insufficiency, mild hypercalcemia, and severe osteoporosis; transplant ineligible

1st line

VRd induction → lenalidomide maintenance (VGPR for 36 months); developed persistent peripheral neuropathy during induction

1st relapse

Relapse confirmed after consecutive labs showed increase of M-protein and light chains, recurrence of hypercalcemia, and reappearance of renal insufficiency

2nd-line treatment considerations for Ben

  • Elderly
  • Impaired renal function
  • Refractory to lenalidomide
  • Developed neuropathy from prior bortezomib treatment
  • Candidate for a triplet combination that includes a multimodal anti-CD38 mAb and a third-generation IMiD®

consider sarclisa + Pd as early as first relapsefor elderly patients and patients with impaired renal function1

PFS in the intent-to-treat population1

  • mPFS: 11.53 months with SARCLISA + Pd (n=154) vs 6.47 months with Pd alone (n=153), HR=0.596 (95% CI: 0.44, 0.81; P=0.0010)

This is a hypothetical case study portrayed by an actor and should not substitute a healthcare provider's decision.

ECOG PS=Eastern Cooperative Oncology Group performance status; eGFR=estimated glomerular filtration rate; IMiD=immunomodulatory drug; mAb=monoclonal antibody; M-protein=monoclonal protein; mPFS=median progression-free survival; PFS=progression-free survival; RRMM=relapsed or refractory multiple myeloma; VGPR=very good partial response; VRd=bortezomib, lenalidomide, dexamethasone.

PFS results in elderly patients and
patients with impaired renal function

In icaria-MM, 20% of patients were elderly (≥75 years) and
36% had impaired renal function3*

PFS in elderly patients (≥75 years)2,3

52%
Reduction in the risk of
disease progression
HR=0.48 (95% CI: 0.24, 0.95)

PFS in patients with renal impairment2,3

50%
Reduction in the risk of
disease progression
HR=0.50 (95% CI: 0.30, 0.85)

See the full icaria-mm patient subgroup data

Study limitations

Prespecified subgroup analysis; subgroups were not powered to show differences between treatment arms.

*eGFR <60 mL/min/1.73 m2.1

Review the broad and diverse patient population studied in the phase 3 ICARIA-MM trial1

See ICARIA-MM Trial Design

Get in touch with your local SARCLISA representative

Contact a Rep
View ikema Patient Profiles
Back to topTop